SIRIC - Cancérologie Marseille

SIRIC Marseille

Publications

Cancer du sein

Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts.
Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, Hong S, Adams A, D’Angelo R, Ginestier C, Charafe-Jauffret E, Clouthier SG, Birnbaum D, Wong ST, Zhan M, Chang JC, Wicha MS.
Stem Cell Reports. 2013 Dec 27 ;2(1):78-91.

Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling.
Cornen S, Guille A, Adélaïde J, Addou-Klouche L, Finetti P, Saade MR, Manai M, Carbuccia N, Bekhouche I, Letessier A, Raynaud S, Charafe-Jauffret E, Jacquemier J, Spicuglia S, de The H, Viens P, Bertucci F, Birnbaum D, Chaffanet M. 
PLoS One. 2014 Jan 9 ;9(1):e81843.

Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.
Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans WF, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT.
Breast Cancer Res. 2013 Nov 25 ;15(6):R112.

ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.
Charafe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti P, Josselin E, Adelaide J, Nguyen TT, Monville F, Jacquemier J, Thomassin-Piana J, Pinna G, Jalaguier A, Lambaudie E, Houvenaeghel G, Xerri L, Harel-Bellan A, Chaffanet M, Viens P, Birnbaum D.
Cancer Res. 2013 Dec 15 ;73(24):7290-300

The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
Salvador MA, Wicinski J, Cabaud O, Toiron Y, Finetti P, Josselin E, Lelièvre H, Kraus-Berthier L, Depil S, Bertucci F, Collette Y, Birnbaum D, Charafe-Jauffret E, Ginestier C.
Clin Cancer Res. 2013 Dec 1 ;19(23):6520-31

Difference in therapeutic response between basal and nonbasal triple-negative breast cancers.
Bertucci F, Finetti P, Viens P, Birnbaum D.
Oncologist 2013 ;18(9):1060-1.

Signaling pathway switch in breast cancer.
Guille A, Chaffanet M, Birnbaum D.
Cancer Cell Int. 2013 Jun 27 ;13(1):66.

Gene expression profiling of solitary fibrous tumors.
Bertucci F, Bouvier-Labit C, Finetti P, Metellus P, Adelaide J, Mokhtari K, Figarella-Branger D, Decouvelaere AV, Miquel C, Coindre JM, Birnbaum D.
PLoS One. 2013 May 29 ;8(5):e64497.

Uncovering the molecular secrets of Inflammatory Breast Cancer biology : An integrated analysis of three distinct Affymetrix gene expression data sets.
Van Laere SJ, Ueno NT, Finetti P, Vermeulen PB, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam PA, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix LY, Reuben JM, Bertucci F.
Clin Cancer Res. 2013 Sep 1 ;19(17):4685-96.

Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets.
Mamessier E, Pradel LC, Thibult ML, Drevet C, Zouine A, Jacquemier J, Houvenaeghel G, Bertucci F, Birnbaum D, Olive D.
J Immunol. 2013 Mar 1 ;190(5):2424-36.


Leucémies Myéloïdes Aigües et Myelodysplasies

Concomitant germ-line RUNX1 and acquired ASXL1 mutations in a T-cell acute lymphoblastic leukemia.
Prebet T, Carbuccia N, Raslova H, Favier R, Rey J, Arnoulet C, Vey N, Vainchenker W, Birnbaum D, Mozziconacci MJ. Eur J Haematol. 2013 Sep ;91(3):277-9.

Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia.
Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Adès L, Fenaux P, Beyne-Rauzy O, Vey N, Braun T, Haferlach T, Dreyfus F, Cross NC, Preudhomme C, Bernard OA, Fontenay M, Vainchenker W, Schnittger S, Birnbaum D, Droin N, Solary E. J Clin Oncol. 2013 Jul 1 ;31(19):2428-36.

Nelarabine for T-cell Acute Lymphoblastic Leukemia relapsing after allogeneic Hematopoietic Stem Cell Transplantation : an opportunity to improve survival.
Forcade E, Leguay T, Vey N, Baruchel A, Delaunay J, Robin M, Socié G, Dombret H, Peffault de Latour R, Raffoux E. Biol Blood Marrow Transplant. 2013 Jul ;19(7):1124-6.

A Phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.
Ossenkoppele GJ, Lowenberg B, Zachee P, Vey N, Breems D, Van de Loosdrecht AA, Davidson AH, Wells G, Needham L, Bawden L, Toal M, Hooftman L, Debnam PM. Br J Haematol. 2013 Jul ;162(2):191-201.

Targeting age-related changes in the biology of acute myeloid leukemia : is the patient seeing the progress ?.
Vey N. Interdiscip Top Gerontol. 2013 ;38:73-84.

Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) : A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
Bally C, Thépot S, Quesnel B, Vey N, Dreyfus F, Fadlallah J, Turlure P, de Botton S, Dartigeas C, de Renzis B, Itzykson R, Fenaux P, Adès L.
Leuk Res. 2013 Jun ;37(6):637-40.

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terré C, Guardiola P, Béné MC, Preudhomme C, Ifrah N, Dombret H ; French AML Intergroup.
Blood. 2013 Mar 21 ;121(12):2213-23.

Allogeneic stem cell transplantation for chronic myelomonocytic leukemia : a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.
Park S, Labopin M, Yakoub-Agha I, Delaunay J, Dhedin N, Deconinck E, Michallet M, Robin M, De Revel T, Bernard M, Vey N, Lioure B, Lapusan S, Tabrizi R, Bourhis JH, Huynh A, Beguin Y, Socié G, Dreyfus F, Fenaux P, Mohty M. Eur J Haematol. 2013 May ;90(5):355-64.

Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases.
Crocchiolo R, Esterni B, Castagna L, Fürst S, El-Cheikh J, Devillier R, Granata A, Oudin C, Calmels B, Chabannon C, Bouabdallah R, Vey N, Blaise D.
Cancer. 2013 Mar 1 ;119(5):986-92.

Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia.
Devillier R, Crocchiolo R, Etienne A, Prebet T, Charbonnier A, Fürst S, El-Cheikh J, D’Incan E, Rey J, Faucher C, Blaise D, Vey N. Leuk Lymphoma. 2013 Jun ;54(6):1228-34.

Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.
Gelsi-Boyer V, Cervera N, Bertucci F, Brecqueville M, Finetti P, Murati A, Arnoulet C, Mozziconacci MJ, Mills KI, Cross NC, Vey N, Birnbaum D. Haematologica. 2013 Apr ;98(4):576-83.

Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation : single-center experience.
El-Cheikh J, Crocchiolo R, Furst S, Ladaique P, Castagna L, Faucher C, Calmels B, Oudin C, Lemarie C, Granata A, Devillier R, Vey N, Bouabdallah R, Chabannon C, Blaise D. Exp Hematol. 2013 Jan ;41(1):17-27.

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.
Prébet T, Thepot S, Gore SD, Dreyfus F, Fenaux P, Vey N. Haematologica. 2013 Feb ;98(2):e18-9.


Gliomes

Ex vivo cultures of glioblastoma in 3-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening.
Jiguet-Jiglaire C, et al., Exp. Cell Res. 2014 Feb 15 ;321(2):99-108.

MALDI imaging and in source decay for top down characterization of glioblastoma.
Ait Belkacem R, et al Proteomics 2013 Dec 23. doi : 10.1002/pmic.201300329

Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.
Chappé C, et al. Brain Pathol. 2013 ;23(5):574-83.

Glial and glioneuronal tumors in adults and children : main genetic alterations and towards a histomolecular classification.
Figarella-Branger D, et al. Bull Cancer. 2013 ;100(7-8)

An orthotopic glioblastoma mouse model maintaining brain parenchymal physical constraints and suitable for intravital two-photon microscopy.
Ricard C, et al. J Visualized Exp. 2014 Apr 21 ;(86). doi : 10.3791/51108

Anti-migratory effect of vinflunine in endothelial and glioblastoma cells is associated with changes in EB1 C-terminal detyrosinated/tyrosinated status.
Rovini A, et al. PLOS One 2013 Sep 12 ;8(9):e72655.

Dynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel density.
Ricard C, et al. PLoS One. 2013 Sep 12 ;8(9):e72655.

Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
Tabouret E, et al. J Neurooncol. 2013 ;114(2):191-8.

Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma.
Mercurio S, et al. Acta Neuropathol Commun. 2013 ;1(1):17.


Cancer du pancréas

Pancreatic Cancer-Induced Cachexia Is Jak2-Dependent in Mice.
GILABERT M, CALVO E, AIROLDI A, HAMIDI T, MOUTARDIER V, TURRINI O, and IOVANNA J.
J. Cell. Physiol. 9999 : 1–7, 2014.

Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs.
Gilabert M, Vaccaro MI, Fernandez-Zapico ME, Calvo EL, Turrini O, Secq V, Garcia S, Moutardier V, Lomberk G, Dusetti N, Urrutia R, Iovanna JL.
J Cell Physiol. 2013 Sep ;228(9):1834-43.

Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma.
Guillaumond F, Leca J, Olivares O, Lavaut MN, Vidal N, Berthezène P, Dusetti NJ, Loncle C, Calvo E, Turrini O, Iovanna JL, Tomasini R, Vasseur S.
Proc Natl Acad Sci U S A. 2013 Mar 5 ;110(10):3919-24.

Mechanistic insights into self-reinforcing processes driving abnormal histogenesis during the development of pancreatic cancer.
Iovanna JL, Marks DL, Fernandez-Zapico ME, Urrutia R.
Am J Pathol. 2013 Apr ;182(4):1078-86.

Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis.
McCleary-Wheeler AL, Lomberk GA, Weiss FU, Schneider G, Fabbri M, Poshusta TL, Dusetti NJ, Baumgart S, Iovanna JL, Ellenrieder V, Urrutia R, Fernandez-Zapico ME.
Cancer Lett. 2013 Jan 28 ;328(2):212-21.

NUPR1 works against the metabolic stress-induced autophagy-associated cell death in pancreatic cancer cells.
Hamidi T, Cano CE, Grasso D, Garcia MN, Sandi MJ, Calvo EL, Dagorn JC, Lomberk G, Goruppi S, Urrutia R, Carracedo A, Velasco G, Iovanna JL.
Autophagy. 2013 Jan ;9(1):95-7

Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma.
Guillaumond F., Leca J., Olivares O., Lavaut M.N., Vidal N., Berthezène P., Dusetti N., Loncle C., Calvo E., Iovanna J.L., Tomasini R., Vasseur S.
Proc. Natl. Acad. Sci. USA. 110:3919-3924, 2013.

The metabolic facet of pancreatic cancer : how hypoxia shapes fatal cancer cells.
Guillaumond F, Vasseur S.
Cell Cycle. 2013 Apr 15 ;12(8):1155-6.

Pancreatic tumor cell metabolism : focus on glycolysis and its connected metabolic pathways.
Guillaumond F., Iovanna J.L., Vasseur S.
Arch Biochem Biophys 2014 Jan 3 ;545C:69-73.

Targeting a novel onco-glycoprotein antigen at tumoral pancreatic cell surface by mAb16D10 induces cell death.
Crescence L, Beraud E, Sbarra V, Bernard JP, Lombardo D, Mas E.
J Immunol. 2012 ;189:3386-96.

Investigation of a new tumor-associated glycosylated antigen as target for dendritic cell vaccination in pancreatic cancer.
Béraud E, Collignon A, Franceschi C, Olive D, Lombardo D, Mas E.
Oncoimmunology. 2012 ;1:56-61


Partenaires SIRIC